Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.


The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page


My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1991 1
2007 2
2009 1
2011 1
2012 3
2014 2
2015 1
2016 1
2018 3
2019 3
2020 6
2021 3
2022 5
2023 4
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

34 results

Results by year

Filters applied: . Clear all
Page 1
Pan-cancer efficacy of pralsetinib in patients with RET fusion-positive solid tumors from the phase 1/2 ARROW trial.
Subbiah V, Cassier PA, Siena S, Garralda E, Paz-Ares L, Garrido P, Nadal E, Vuky J, Lopes G, Kalemkerian GP, Bowles DW, Seetharam M, Chang J, Zhang H, Green J, Zalutskaya A, Schuler M, Fan Y, Curigliano G. Subbiah V, et al. Among authors: seetharam m. Nat Med. 2022 Aug;28(8):1640-1645. doi: 10.1038/s41591-022-01931-y. Epub 2022 Aug 12. Nat Med. 2022. PMID: 35962206 Free PMC article. Clinical Trial.
Dual checkpoint targeting of B7-H3 and PD-1 with enoblituzumab and pembrolizumab in advanced solid tumors: interim results from a multicenter phase I/II trial.
Aggarwal C, Prawira A, Antonia S, Rahma O, Tolcher A, Cohen RB, Lou Y, Hauke R, Vogelzang N, P Zandberg D, Kalebasty AR, Atkinson V, Adjei AA, Seetharam M, Birnbaum A, Weickhardt A, Ganju V, Joshua AM, Cavallo R, Peng L, Zhang X, Kaul S, Baughman J, Bonvini E, Moore PA, Goldberg SM, Arnaldez FI, Ferris RL, Lakhani NJ. Aggarwal C, et al. Among authors: seetharam m. J Immunother Cancer. 2022 Apr;10(4):e004424. doi: 10.1136/jitc-2021-004424. J Immunother Cancer. 2022. PMID: 35414591 Free PMC article. Clinical Trial.
Phase II Study of Olaparib and Temozolomide for Advanced Uterine Leiomyosarcoma (NCI Protocol 10250).
Ingham M, Allred JB, Chen L, Das B, Kochupurakkal B, Gano K, George S, Attia S, Burgess MA, Seetharam M, Boikos SA, Bui N, Chen JL, Close JL, Cote GM, Thaker PH, Ivy SP, Bose S, D'Andrea A, Marino-Enriquez A, Shapiro GI, Schwartz GK. Ingham M, et al. Among authors: seetharam m. J Clin Oncol. 2023 Sep 1;41(25):4154-4163. doi: 10.1200/JCO.23.00402. Epub 2023 Jul 19. J Clin Oncol. 2023. PMID: 37467452
First-Line Therapy for Metastatic Soft Tissue Sarcoma.
Meyer M, Seetharam M. Meyer M, et al. Among authors: seetharam m. Curr Treat Options Oncol. 2019 Jan 24;20(1):6. doi: 10.1007/s11864-019-0606-9. Curr Treat Options Oncol. 2019. PMID: 30675651 Review.
Undifferentiated Pleomorphic Sarcoma Presenting as Hip Pain.
Huff D, Horsley RK, Seetharam M, Larsen BT. Huff D, et al. Among authors: seetharam m. Am J Med. 2023 Sep;136(9):e171-e172. doi: 10.1016/j.amjmed.2023.04.015. Epub 2023 May 4. Am J Med. 2023. PMID: 37148991 No abstract available.
34 results